Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440388 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
A Phase 2 study of Follicular Lymphoma, sponsored by Ascenta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 20
- Study locations
NCT00440388 is a Phase 2 study of Follicular Lymphoma that has completed, run by Ascenta Therapeutics. The registered enrollment target is 23 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT00440388, a Phase 2 study of Follicular Lymphoma, has completed, sponsored by Ascenta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this disease, with AT-101, an experimental drug. The hypothesis is that by adding AT-101 to the rituximab regimen, improvement to patients' response to the treatment will be observed verses rituximab alone.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG AT-101
Study Locations (20)
Texas
- Texas Oncology, P.A. - Bedford
- Texas Cancer Center at Medical City - Dallas
- Texas Oncology, P.A. - Fort Worth
- Allison Cancer Center - Midland
Florida
- Florida Cancer Institute - Hudson
- Florida Cancer Institute - New Port Richey
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Hematology Oncology Associates - Phoenix
Colorado
- Rocky Mountain Cancer Center-Aurora - Aurora
Illinois
- Cancer Care & Hematology Specialists of Chicagoland - Arlington Heights
Indiana
- Central Indiana Cancer Centers - Fishers
Michigan
- University of Michigan Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440388
The ClinicalTrials.gov registry entry for NCT00440388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is Ascenta Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT00440388 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Texas, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00440388 about?
NCT00440388 is a clinical study titled "Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma". This is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this disease, with AT-101, an experimental drug. The hypothesis is that by adding AT-101 to the rituximab regimen, improvem...
What is the current status of trial NCT00440388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2006-10. Estimated completion is 2008-11.
What conditions does trial NCT00440388 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT00440388?
The interventions under investigation include: Rituximab (DRUG), AT-101 (DRUG).
Who is sponsoring clinical trial NCT00440388?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00440388 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.